Short Interest in Longeveron Inc. (NASDAQ:LGVN) Decreases By 21.2%

Longeveron Inc. (NASDAQ:LGVN) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 586,100 shares, a decrease of 21.2% from the January 15th total of 743,400 shares. Approximately 13.1% of the company’s shares are sold short. Based on an average trading volume of 307,600 shares, the short-interest ratio is presently 1.9 days.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Roth Mkm assumed coverage on shares of Longeveron in a research note on Friday, December 6th. They issued a “buy” rating and a $10.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Longeveron in a research note on Monday, November 25th. Finally, Roth Capital raised shares of Longeveron to a “strong-buy” rating in a research note on Thursday, December 5th.

Longeveron Price Performance

Shares of NASDAQ LGVN opened at $1.57 on Friday. Longeveron has a fifty-two week low of $0.77 and a fifty-two week high of $6.40. The company has a 50 day simple moving average of $1.73 and a two-hundred day simple moving average of $2.02.

Longeveron (NASDAQ:LGVN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.19. Longeveron had a negative net margin of 967.49% and a negative return on equity of 142.43%. The business had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.34 million. During the same quarter last year, the firm earned ($2.80) earnings per share. Analysts predict that Longeveron will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Longeveron

Institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp bought a new position in shares of Longeveron during the third quarter valued at approximately $29,000. Virtu Financial LLC purchased a new stake in shares of Longeveron during the fourth quarter valued at approximately $53,000. Finally, Geode Capital Management LLC grew its holdings in shares of Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares during the last quarter. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.